You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Suppliers and packagers for generic pharmaceutical drug: pegulicianine acetate


✉ Email this page to a colleague

« Back to Dashboard


pegulicianine acetate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511 NDA Lumicell, Inc. 82292-040-10 10 VIAL in 1 CARTON (82292-040-10) / 3.9 mL in 1 VIAL (82292-040-01) 2024-04-17
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: PEGULICIANINE ACETATE

Last updated: August 4, 2025

Introduction

PEGULICIANINE ACETATE, a synthetic opioid analgesic, has drawn significant interest amid evolving pain management therapies. Given its potential clinical applications, the demand for reliable suppliers is critical for pharmaceutical companies and healthcare providers. This article explores the current landscape of PEGULICIANINE ACETATE suppliers, including manufacturers, geographic distribution, regulatory considerations, and market trends impacting the drug's procurement and distribution.

Understanding PEGULICIANINE ACETATE

PEGULICIANINE ACETATE is a synthetic compound under investigation for its analgesic potency and unique receptor activity. Its chemical structure and therapeutic promise render it a candidate for advanced pain relief formulations. As a proprietary or investigational pharmaceutical, the supply chain is often concentrated among specialized chemical and pharmaceutical manufacturers with expertise in complex synthetic opioids.

Key Characteristics of the Supply Chain

Manufacturer Profile and Production Capabilities

Suppliers for PEGULICIANINE ACETATE are primarily specialized chemical synthesis companies and contract manufacturing organizations (CMOs) with experience in complex opioid synthesis. These entities typically possess certified facilities compliant with Good Manufacturing Practices (GMP), ensuring quality and regulatory adherence.

Leading firms in this space are often involved in the synthesis of a broad portfolio of opioid compounds, with capabilities spanning from research quantities to commercial-scale production. Their technical expertise in handling controlled substances is vital, given regulatory scrutiny.

Major Suppliers and Their Geographic Distribution

  1. United States:
    The U.S. hosts several high-capacity chemical synthesis firms with expertise in controlled substance manufacturing, such as Certara, Piramal Pharma Solutions, and dedicated divisions within larger pharmaceutical groups. These companies often serve both domestic and international markets, adhering to strict FDA cGMP guidelines.

  2. Europe:
    European suppliers include specialized companies like Eli Lilly (through legacy divisions) and smaller chemical manufacturing firms in Germany, Switzerland, and the UK. European suppliers benefit from stringent regulatory frameworks and advanced chemical synthesis capabilities.

  3. Asia:
    China and India dominate the production landscape for many pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Notably, Chinese chemical manufacturers such as Hubei Fullspring and Indian firms like Lupin Ltd. and Sun Pharma are strategically positioned as potential PEGULICIANINE ACETATE suppliers, leveraging large-scale manufacturing infrastructure and cost advantages.

Contract Manufacturing and Custom Synthesis

Given the niche status of PEGULICIANINE ACETATE, many pharmaceutical developers rely on CMOs for synthesis. Contracting with specialized firms allows for scalable production, risk mitigation, and regulatory compliance. Many of these CMOs operate globally but often source precursor chemicals or intermediates from major chemical hubs.

Regulatory Considerations

As a controlled substance with potential for misuse, PEGULICIANINE ACETATE suppliers must operate under strict compliance with international and national regulations, including:

  • DEA Regulations (U.S.)
  • European Drug Control Agencies
  • International Narcotics Control Board (INCB)

Manufacturers require specific licenses and rigorous audit trails. These regulatory hurdles can influence supplier choices, favoring established, compliant firms with proven track records.

Market Trends and Challenges in Supplier Procurement

Supply Chain Security

The global supply chain for controlled substances faces disruptions due to geopolitical tensions, regulatory changes, and recent supply restrictions stemming from increased scrutiny over opioid manufacturing. These factors necessitate diversified sourcing strategies across multiple regions to ensure continuity.

Pricing Dynamics

Limited supply sources coupled with high regulatory burdens often lead to elevated procurement costs. Pharma companies and research institutions must negotiate contracts carefully, balancing cost with quality assurance.

Emergence of New Suppliers

Recent developments include the entry of emerging chemical manufacturers, particularly in Asia, driven by advances in synthetic chemistry and increased international collaboration. These new suppliers may offer competitive pricing but require thorough vetting for quality and compliance.

Intellectual Property and Licensing

In some cases, proprietary synthesis routes or licensing agreements influence supplier availability. Manufacturers holding patents on specific synthetic pathways might restrict access, channeling supply through authorized distributors or licensing partners.

Future Outlook

As research into PEGULICIANINE ACETATE advances, demand for this compound may increase, especially if clinical trials demonstrate significant therapeutic benefits. This scenario will likely incentivize existing suppliers to expand production capacities or new entrants to establish manufacturing capabilities. Regulatory harmonization and streamlined approval processes could further ease supplier onboarding.

In addition, advances in synthetic chemistry may lead to alternative or more efficient production methods, potentially broadening the supplier base.

Key Challenges for Procurement

  • Regulatory Complexity: Navigating controlled substance regulations remains a major barrier, requiring compliance infrastructure and licensing.
  • Limited Market Size: The niche status of PEGULICIANINE ACETATE constrains supply chain investments.
  • Quality Assurance: Ensuring consistent quality from suppliers is critical, especially given the compound's controlled nature.
  • Supply Chain Disruptions: Political, economic, or pandemic-related disruptions impact global sourcing.

Conclusion

The procurement of PEGULICIANINE ACETATE hinges on a limited but specialized group of suppliers capable of meeting regulatory and quality standards. Principal sourcing regions include North America, Europe, and Asia, with Chinese and Indian manufacturers playing growing roles. Stakeholders must prioritize supplier compliance, diversify sourcing strategies, and establish robust regulatory oversight to secure consistent and safe supply lines.


Key Takeaways

  • PEGULICIANINE ACETATE suppliers are primarily specialized chemical manufacturers with GMP compliance, often based in North America, Europe, and Asia.
  • Asian manufacturers, especially Chinese and Indian firms, are increasingly significant due to cost advantages and manufacturing capacity.
  • Regulatory compliance and licensing are critical in choosing suppliers, given the compound's controlled substance status.
  • Supply chain disruptions and regulatory hurdles pose ongoing challenges, emphasizing the importance of diversified sourcing.
  • Market evolution, including technological advances and regulatory changes, will influence supplier landscape dynamics.

FAQs

1. Are there any major pharmaceutical companies manufacturing PEGULICIANINE ACETATE at scale?
Currently, PEGULICIANINE ACETATE remains largely in the research or early development stages, with manufacturing typically performed by specialized chemical firms or CMOs. Major pharmaceutical companies may not produce at commercial scale unless clinical or regulatory approval is achieved.

2. What regulatory hurdles must suppliers overcome to produce PEGULICIANINE ACETATE?
Suppliers must obtain specific licenses from authorities like the DEA or equivalent agencies, demonstrate GMP compliance, and maintain rigorous recordkeeping due to its status as a controlled substance. International restrictions also mandate adherence to treaties overseen by bodies like the INCB.

3. Can new suppliers enter the PEGULICIANINE ACETATE market easily?
Entry is challenging due to strict regulation, the need for specialized synthetic expertise, and the requirement for licensing and compliance infrastructure. However, technological advancements could facilitate new entrants in the future.

4. How does geopolitical instability influence the PEGULICIANINE ACETATE supply chain?
Instability can disrupt manufacturing, export-import regulations, and transportation logistics. Diversifying suppliers across regions mitigates risks associated with political or geopolitical issues.

5. What role do contract manufacturing organizations play in the supply of PEGULICIANINE ACETATE?
CMOs facilitate synthesis, scale-up, and regulatory compliance, allowing pharma companies to outsource manufacturing, ensure supply continuity, and reduce time-to-market risks, especially in niche or controlled substances.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.